Digital Health Company Akili Interactive To Become Publicly Traded Through Combination With SPAC

Akili Interactive, which develops digital health technology to treat cognitive impairments, entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC). Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in gross cash proceeds. The transaction will fund the commercial launch of Akili’s flagship product, EndeavorRx® for pediatric attention deficit/hyperactivity disorder (ADHD).

EndeavorRx is a digital therapeutic for pediatric attention deficit/hyperactivity disorder (ADHD). It . . .